Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vapreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 0.80 |
| ▸ | SSTR5 known ✓ | P35346 | 15/20 | 0.80 |
| ▸ | SSTR3 known ✓ | P32745 | 8/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.78 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vapreotide SCHEMBL29384009 | 1.00 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL294911 | 1.00 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL30163296 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4826 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29405608 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4827 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL31632623 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL6369050 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL5200070 | 0.97 | SSTR2 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| SCHEMBL23482743 | 0.97 | SSTR5 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381290-A1 | Antibody Conjugates and Methods of Making and Using the Same | SCHERER TECHNOLOGIES LLC R P (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250262315-A1 | TRIPEPTIDE LINKERS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-21 | — | — | US | disclosed |
| EP-4592275-A2 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | Redwood Bioscience, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3074010-B1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | REDWOOD BIOSCIENCE INC (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12296021-B2 | Antibody conjugates and methods of making and using the same | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250115546-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | UNIV TEXAS (US) | 2025-04-10 | — | — | US | disclosed |
| US-12215080-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCE, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452292-A2 | TRIPEPTIDE LINKERS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-111065623-B9 | Linker for antibody drug conjugates | 德克萨斯州大学系统董事会 | 2024-10-25 | — | — | CN | disclosed |
| CN-118652192-A | Linker for antibody drug conjugates | 德克萨斯州大学系统董事会 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023122587-A2 | TRIPEPTIDE LINKERS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11629122-B2 | Linkers for antibody drug conjugates | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230068124-A1 | Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-03-02 | — | — | US | disclosed |
| CN-115504924-A | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11466096-B2 | Antibody conjugates and methods of making and using the same | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-10-11 | — | — | US | disclosed |
| CN-105744935-B | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11426465-B2 | Hydrazinyl-indole compounds and methods for producing a conjugate | Redwiid Bioscience, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220153696-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-05-19 | — | — | US | disclosed |
| US-20220145270-A1 | Antibody Conjugates and Methods of Making and Using the Same | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068124-A1 | Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate | HNMT, AANAT, INMT | SSTR2 628/4885SSTR5 84/4885SSTR3 445/4885 |
| US-20220153696-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | DNPEP, QPCT, PDS5A | SSTR2 3008/4885SSTR5 802/4885SSTR3 2594/4885 |
| US-20250115546-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | CD47, EPCAM, SDCBP | SSTR2 2302/4885SSTR5 789/4885SSTR3 2121/4885 |
| US-11426465-B2 | Hydrazinyl-indole compounds and methods for producing a conjugate | HNMT, AANAT, INMT | SSTR2 628/4885SSTR5 84/4885SSTR3 445/4885 |
| US-20250381290-A1 | Antibody Conjugates and Methods of Making and Using the Same | PFAS, FGR, FGB | SSTR2 3589/4885SSTR5 2312/4885SSTR3 2313/4885 |
| US-20250262315-A1 | TRIPEPTIDE LINKERS AND METHODS OF USE THEREOF | DNPEP, VIP, LNPEP | SSTR2 1545/4885SSTR5 623/4885SSTR3 607/4885 |
| US-12215080-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | DNPEP, QPCT, PDS5A | SSTR2 3008/4885SSTR5 802/4885SSTR3 2594/4885 |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | HNMT, TIAL1, HACL2 | SSTR2 3211/4885SSTR5 1345/4885SSTR3 2259/4885 |
| US-11629122-B2 | Linkers for antibody drug conjugates | CD47, EPCAM, FCGRT | SSTR2 2082/4885SSTR5 571/4885SSTR3 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.